A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001)

Complete Title: A Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-Tumor Activity of PF-07260437 in Advanced or Metastatic Solid Tumors

Trial Phase: I

Investigator: Jennifer Specht, MD

A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged =18 years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer. Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be considered after discussion with and approval from sponsor.

Keywords:

Breast Cancer
Endometrial Cancer
Ovarian Cancer

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.